Login to Your Account



Amarin to Launch Vascepa Alone with $100M Debt Financing

By Catherine Shaffer
Staff Writer

Monday, December 10, 2012
In a conference call last week, Amarin Corp. plc CEO Joe Zakrzewski insisted that it would be "a mistake" to assume that the company's decision to launch Vascepa (icosapent ethyl) on its own through the use of a $100 million debt instrument meant that it had abandoned its search for a partner for the fish oil-based product it is developing for the cardiovascular disease market.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription